Posts

Merck scored another big win Wednesday with a U.S. Food and Drug Administration approval for an expanded indication of Vaxneuvance, its pneumococcal 15-valent conjugate vaccine. The new indication includes children 6 weeks through 17 years of age.

GSK on Tuesday agreed to buy U.S. biotech Affinivax for up to $3.3 billion, its second major deal in two months, giving the British pharmaceutical giant access to the privately held company’s roster of next-generation vaccines.